Summary
Global Markets Direct’s, ‘Constipation - Pipeline Review, H2 2016’, provides an overview of the Constipation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Constipation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Constipation and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Constipation
- The report reviews pipeline therapeutics for Constipation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Constipation therapeutics and enlists all their major and minor projects
- The report assesses Constipation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Constipation
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Constipation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AlbireoPharma
Ardelyx, Inc.
Astellas Pharma Inc.
Braintree Laboratories, Inc.
CJ HealthCare Corp.
EA Pharma Co Ltd
Ironwood Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Motus Therapeutics Inc
NGM Biopharmaceuticals, Inc.
RaQualia Pharma Inc.
Sa
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Constipation Overview 9
Therapeutics Development 10
Pipeline Products for Constipation - Overview 10
Pipeline Products for Constipation - Comparative Analysis 11
Constipation - Therapeutics under Development by Companies 12
Constipation - Therapeutics under Investigation by Universities/Institutes 14
Constipation - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Constipation - Products under Development by Companies 18
Constipation - Products under Investigation by Universities/Institutes 20
Constipation - Companies Involved in Therapeutics Development 21
AlbireoPharma 21
Ardelyx, Inc. 22
Astellas Pharma Inc. 23
Braintree Laboratories, Inc. 24
CJ HealthCare Corp. 25
EA Pharma Co Ltd 26
Ironwood Pharmaceuticals, Inc. 27
Kissei Pharmaceutical Co., Ltd. 28
Motus Therapeutics Inc 29
NGM Biopharmaceuticals, Inc. 30
RaQualia Pharma Inc. 31
Sanwa Kagaku Kenkyusho Co., Ltd. 32
Shire Plc 33
SK Biopharmaceuticals Co., Ltd. 34
Sucampo Pharmaceuticals, Inc. 35
Sumitomo Dainippon Pharma Co., Ltd. 36
Synergy Pharmaceuticals, Inc. 37
Synthetic Biologics, Inc. 38
Torrent Pharmaceuticals Limited 39
Yuhan Corporation 40
Constipation - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
5-BIOP - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
AJG-555 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ASP-7663 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
BLI-400 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
BLI-801 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
CJ-14199 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
DA-6886 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
DSP-6952 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
elobixibat - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
KWA-0711 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
linaclotide - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
lovastatin - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
lubiprostone - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
NGM-282 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
plecanatide - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
prucalopride succinate - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
prucalopride succinate - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
relamorelin - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
relenopride hydrochloride - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
RQ-00000010 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
SK-1202 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
tenapanor hydrochloride - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Transilon - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
YH-12852 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
Constipation - Dormant Projects 107
Constipation - Product Development Milestones 108
Featured News & Press Releases 108
Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review 108
May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin 108
May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 108
May 22, 2016: Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week 110
May 21, 2016: Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week 110
May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016 112
May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 113
May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016 113
May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development 114
Apr 19, 2016: Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation 115
Feb 29, 2016: Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS (linaclotide) 115
Feb 17, 2016: Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation 115
Jan 29, 2016: Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation 116
Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) 117
Dec 08, 2015: Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) 118
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 120
Disclaimer 121
List of Tables
Number of Products under Development for Constipation, H2 2016 10
Number of Products under Development for Constipation - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Constipation - Pipeline by AlbireoPharma, H2 2016 21
Constipation - Pipeline by Ardelyx, Inc., H2 2016 22
Constipation - Pipeline by Astellas Pharma Inc., H2 2016 23
Constipation - Pipeline by Braintree Laboratories, Inc., H2 2016 24
Constipation - Pipeline by CJ HealthCare Corp., H2 2016 25
Constipation - Pipeline by EA Pharma Co Ltd, H2 2016 26
Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 27
Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 28
Constipation - Pipeline by Motus Therapeutics Inc, H2 2016 29
Constipation - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 30
Constipation - Pipeline by RaQualia Pharma Inc., H2 2016 31
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 32
Constipation - Pipeline by Shire Plc, H2 2016 33
Constipation - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 34
Constipation - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 35
Constipation - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 36
Constipation - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016 37
Constipation - Pipeline by Synthetic Biologics, Inc., H2 2016 38
Constipation - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 39
Constipation - Pipeline by Yuhan Corporation, H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Constipation - Dormant Projects, H2 2016 107
List of Figures
Number of Products under Development for Constipation, H2 2016 10
Number of Products under Development for Constipation - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Targets, H2 2016 42
Number of Products by Stage and Targets, H2 2016 42
Number of Products by Mechanism of Actions, H2 2016 44
Number of Products by Stage and Mechanism of Actions, H2 2016 44
Number of Products by Routes of Administration, H2 2016 46
Number of Products by Stage and Routes of Administration, H2 2016 46
Number of Products by Molecule Types, H2 2016 48
Number of Products by Stage and Molecule Types, H2 2016 48
